Ignacio I. Wistuba

Research interests

Publications

• PD-L1 as a biomarker of response to immune-checkpoint inhibitors

  Nature Reviews Clinical Oncology · 2021 · 10.1038/s41571-021-00473-5

• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

  Cancer Cell · 2021 · 10.1016/j.ccell.2020.12.014

• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.06.017

• Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30453-8

• IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.01.005

• Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

  Cancer Discovery · 2019 · 10.1158/2159-8290.cd-18-1020

• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0099

• PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

  Journal of Thoracic Oncology · 2018 · 10.1016/j.jtho.2018.05.013

• Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.75.8219

• Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

  Journal of Thoracic Oncology · 2018 · https://doi.org/10.1016/j.jtho.2018.05.030

• Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

  Cell Metabolism · 2018 · https://doi.org/10.1016/j.cmet.2018.02.024

• A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

  JAMA Oncology · 2017 · 10.1001/jamaoncol.2017.0013

• Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30624-1

• High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx004

• Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

  Cancer Discovery · 2016 · https://doi.org/10.1158/2159-8290.cd-15-1545

• The 2015 World Health Organization Classification of Lung Tumors

  Journal of Thoracic Oncology · 2015 · https://doi.org/10.1097/jto.0000000000000630

• NRF2 regulates serine biosynthesis in non–small cell lung cancer

  Nature Genetics · 2015 · 10.1038/ng.3421

• Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-14-1236

• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

  Nature Communications · 2014 · 10.1038/ncomms6241

• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

  JAMA · 2014 · https://doi.org/10.1001/jama.2014.3741

• Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

  Science · 2014 · 10.1126/science.1256930

• A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients

  Clinical Cancer Research · 2013 · https://doi.org/10.1158/1078-0432.ccr-12-2321

• Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-11-1446

• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-1558

• The BATTLE Trial: Personalizing Therapy for Lung Cancer

  Cancer Discovery · 2011 · 10.1158/2159-8274.cd-10-0010

• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  Journal of Thoracic Oncology · 2011 · https://doi.org/10.1097/jto.0b013e318206a221

• Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

  Clinical Cancer Research · 2010 · https://doi.org/10.1158/1078-0432.ccr-09-3352

• TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs

  Nature · 2010 · https://doi.org/10.1038/nature09459

• Somatic mutations affect key pathways in lung adenocarcinoma

  Nature · 2008 · https://doi.org/10.1038/nature07423

• Characterizing the cancer genome in lung adenocarcinoma

  Nature · 2007 · 10.1038/nature06358

• Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

  Cancer Research · 2005 · 10.1158/0008-5472.can-04-4235

• Epidemiology and Molecular Pathology of Gallbladder Cancer

  CA A Cancer Journal for Clinicians · 2001 · 10.3322/canjclin.51.6.349

Current projects

No projects listed.